October 14, 2021

TFF Pharmaceuticals and Augmenta Bioworks Publish Positive In Vivo Data Showing Dry Powder Formulation of COVID-19 Antibody, AUG-3387, Neutralizes SARS-CoV-2 Infection and Reduces Viral Load

September 23, 2021

TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

September 8, 2021

TFF Pharmaceuticals to Present at 23rd H.C. Wainwright Annual Global Investment Conference

August 12, 2021

TFF Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

August 5, 2021

TFF Pharmaceuticals to Present at the Investor Summit Virtual Conference on August 18, 2021

August 5, 2021

TFF Pharmaceuticals to Present at the SNN Virtual Investor Conference on August 19, 2021

August 4, 2021

TFF Pharmaceuticals to Hold Second Quarter 2021 Financial and Business Results Conference Call on August 12, 2021

July 29, 2021

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating Binding and Neutralization of the SARS-CoV-2 Delta Variant by Lead Anti-COVID-19 Antibody, AUG-3387

July 28, 2021

TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference

July 13, 2021

TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder